



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 082 621
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 82306411.8

(51) Int.Cl.³: A 61 F 1/00

(22) Date of filing: 02.12.82

(30) Priority: 18.12.81 US 332325

(71) Applicant: COLLAGEN CORPORATION
2455 Faber Place
Palo Alto, California 94303(US)

(43) Date of publication of application:
29.06.83 Bulletin 83/26

(72) Inventor: Smestad, Thomas L.
989 Curtner Avenue
San Jose California 95125(US)

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(74) Representative: Harrison, David Christopher et al,
MEWBURN ELLIS & CO 2/3 Cursitor Street
London EC4A 1BQ(GB)

(54) Implantable bone prosthesis.

(57) A flexible, bone prosthesis is disclosed that comprises demineralized bone powder contained within a medical grade porous flexible casing made from polymeric fibers or a microporous membrane. The pores of the casing are smaller than the particle size of the bone powder but large enough to permit ingress of body cells associated with bone formation.

A1
621 082 EP 0

IMPLANTABLE BONE PROSTHESIS

This invention relates to an osteogenic,
5 implantable bone prosthesis comprising demineralized
bone or dentin powder contained in a flexible porous
medical grade casing.

Demineralized bone in both solid and powder
10 form has been used extensively to repair or replace
bone. Once it is implanted, induced osteogenesis
occurs at the implant site and bone is formed. Im-
planted demineralized bone powder, because it is par-
ticulate, is more readily and completely invaded by
15 osteogenic cells than solid, one-piece demineralized
bone. Because of its nature, however, powder is dif-
ficult to form into larger size prostheses of prede-
fined shape. Another problem with implanting bone
powder is that it may migrate and induce bone forma-
20 tion at a remote, undesirable site. A prosthesis made
from solid cancellous bone may allow cellular invasion
throughout the prosthesis because cancellous bone is
inherently porous. But cancellous bone prostheses are
25 limited in shape and size to the source bone shape and
dimensions. Use of one-piece compact bone for pros-
thesis construction would allow the manufacture of
larger implants. Compact bone is, however, inherently
too dense to permit complete cellular invasion and the
interior of a large compact bone prosthesis may remain
30 unossified.

U.S. Patent No. 3,849,805 describes an alloplastic tray that is used as a stress-bearing bone prosthesis, especially for mandibular reconstruction. The tray is made from Dacron or nylon mesh which is 5 dipped in a polyether urethane elastomer and then cured to increase the rigidity of the tray. The patent does not indicate the pore size of the mesh. It is believed that the pore size would have to be greatly in excess of one mm in order to avoid being 10 coated over by the elastomer. The tray contains fresh autologous bone chips.

Buring, K. and Urist, M., Transfilter Bone Induction, Clinical Orthopaedics and Related Research, Vol 54, pp 235-242 (1967) report transfilter bone 15 induction experiments in which millipore membrane diffusion cells intended to be impermeable to host cells were filled with a mixture of minced allogeneic muscle and decalcified, lyophylized bone matrix and implanted in rabbits. Several of the test cells fractured 20 in situ and permitted host connective tissue cells to stream into the cell chamber. Bone induction at the points of contact between the matrix and ingrowing mesenchymal cells was observed.

25 The invention is an implantable bone prosthesis comprising particles of bone dentin or mixtures thereof contained in a porous casing characterized in that the bone or dentin particles are demineralized and the casing is flexible and porous 30 with the pores being smaller than the particle size of the particles but large enough to permit ingress of osteogenic or mesenchymal cells.

The bone or dentin that is used in the invention may be collected from a variety of mammalian sources. Homogeneic and xenogeneic sources may be 5 used. The processing of dentin for use in the invention is essentially the same as the processing of bone for use in the invention. Therefore, in the interest of brevity, only the processing of bone will be hereafter described in detail.

10 The bone may be either cancellous or compact. Bovine and porcine bone, preferably long bone, will normally be used because of its availability. The surface of the bone is first cleaned by physically removing periosteum by scraping or brushing. The bone 15 is then fragmented into small pieces and the fragments are water washed with agitation to remove any water soluble materials remaining on the fragments. The washing is preferably carried out at reduced temperatures that lessen the likelihood of enzymatic degradation. 20 The bone, usually about 4°C to 15°C, with frequent changing of the wash water. The fragments are then dried, extracted with one or more lipophilic solvents, such as ethanol and ethyl acetate, to remove lipids and dehydrate the bone. The fragments are then 25 dried under vacuum and comminuted by crushing, milling, or pulverizing, preferably at reduced temperatures to increase the friability of the bone. The bone is accordingly converted into a finely divided powder having a particle size in the range of about 40 30 to 500 microns, preferably 75 to 250 microns. Division of the bone into small particles facilitates extracting the minerals from it.

 The principal mineral component of bone is calcium phosphate. The term "calcium phosphate" as

used herein is intended to encompass all the calcium-phosphorous complexes and compounds present in bone such as the various polycalcium phosphates, hydroxyapatite, chlorapatite, and the like. Calcium phosphate usually constitutes about 80% by weight of the mineral content of bone. Other mineral components of bone include calcium carbonate, calcium fluoride, calcium chloride, and magnesium phosphate. These minerals are normally soluble in dilute mineral and organic acids and such acids may be used to demineralize bone. The concentration of the acid used to demineralize the bone will usually be between 0.1 M and 1.0 M. Hydrochloric acid at a concentration of 0.5 M is preferred. The bone will normally be contacted with the acid for one hour to several days at reduced temperatures that lessen the likelihood of enzymatic degradation or acid hydrolysis of the bone, typically about 4°C to about 15°C. Agitation facilitates extraction of the minerals from the bone. After the extraction is complete the bone is separated from the acid such as by sedimentation, filtration or other conventional solid-liquid separation techniques and the bone is washed sequentially with water, ethanol, and ether to remove absorbed acid and dehydrate it.

The dried bone may be sterilized by irradiation, ethylene oxide treatment, or other known solids sterilization methods if it is desired to do so before placing it in the casing.

The porous casing in which the demineralized bone or dentin powder is contained is made from a natural or synthetic fibrous or microporous polymer. The casing should be biocompatible that is, it should not be significantly irritating or antigenic. It may be made from polymers that maintain their integrity even

after prolonged emplacement in the body or from polymers that bioerode or otherwise disintegrate after a predetermined time period correlated to the time required for the implant to reach a suitable stage of 5 ossification. In the case of fibrous casings, the fabric may be woven or nonwoven. Examples of woven medical grade fabrics are the Dacron and nylon and carbon fabrics that are commonly used in biomedical devices such as stents, prosthetic tendons, and vascular 10 grafts. Examples of suitable nonwoven fabrics are those made of natural materials such as collagen or synthetic materials such as polyesters, polyamides, or polyolefins that are used as fabric backings for 15 wound dressings. Crosslinked collagen is a preferred fabric material.

Microporous polymers that may be used as casings are characterized as having a sponge-like porous nature. These microporous polymers are made by 20 forming pores in various kinds of dense polymers such as polycarbonates, polyamides, polyesters, polyolefins, polysaccharides, and cellulosics by leaching, orientation, or other well-known pore-forming techniques.

The casing may be formed from a single homogeneous layer of one of the above described fibrous or microporous materials or be a laminate of two or more layers of such materials. In any event the casing must be sufficiently porous to permit ingress of host 30 osteogenic and/or mesenchymal cells into the casing lumen but not so porous as to allow the bone dentin powder contained within the casing lumen to leak out. The maximum pore size will be less than the minimum particle size of the demineralized bone or 35 dentin powder. Accordingly, for embodiments having

particle sizes down to 40 microns, the maximum pore size will be below 40 microns. For the above-mentioned preferred particle size range the maximum pore size will be less than 75 microns. Correspondingly, the minimum pore size will usually be at least 5 5 microns. Preferably, it is about 10-15 microns below the minimum particle size of the demineralized bone or dentin powder.

The fabric-encased osteogenic implant may be assembled from the demineralized bone and/or dentin 10 powder and porous casing in several ways. One assembly technique involves forming an open-ended pouch from the fabric or microporous membrane, depositing the powder in the pouch and then sealing the pouch. Sealing may be accomplished by stitching, adhesives, 15 heat and pressure, or other means depending upon the nature of the casing. Another assembly technique involves forming a closed container from the fabric or microporous membrane and then injecting the bone powder in the form of an aqueous slurry through the 20 casing into the container. The injection site may be sealed with a medical grade sealant or cement if necessary. This latter assembly technique would probably be carried out only as part of the surgical operation. The former technique is preferred. The assembly 25 will be made using sterile components and conditions or, in the case of the former assembly method, the implant may be packaged and terminally sterilized using irradiation, ethylene oxide, or other known suitable solids sterilization methods. The pouch or 30 container may, of course, be fashioned into any desired size or shape before being filled to accommodate the optimum prosthesis size and shape. The fine demineralized bone powder gives the implant a high

effective surface area which facilitates rapid and complete ossification of the implant. In this regard the demineralized powder ossifies at its surface first. In contrast, bone that has not been demineralized is resorbed first and is then ossified. The porosity of the implant permits bone-forming cell permeation throughout the implant and its flexibility allows the implant to be deformed at the time of implantation to an exact fit of the implant site.

10 The assemblies are implanted surgically by known methods. If the implant is dry (i.e. it comprises encased dry demineralized bone powder) it should be wetted with sterile physiological saline or the like before it is implanted. If necessary the
15 assembly may be sutured in place to ensure its immobilization. The assembly will preferably include a sewing ring to facilitate such affixation. After implantation, induced osteogenesis occurs, thus forming bone in the shape of the implanted pouch. If
20 desired, bone growth stimulants such as bone morphogenic protein or those disclosed in U.S. Patent No. 4,191,747 at col. 3, line 50 to col. 4, line 13, which disclosure is incorporated herein by reference, as well as other agents such as anesthetics, hemostats,
25 antibiotics or other drugs, may be included in the assembly either at the time it is assembled or on implantation by injecting, coating or other means of inclusion.

 The implants may be used to replace or
30 repair lost, damaged, or deformed nonstress-bearing bone tissue in living mammals, including humans. In this regard the term "nonstress-bearing" refers to bone tissue that does not normally bear substantial loads, such as craniofacial bone other than the
35 load-bearing parts of the jaw.

CLAIMS

1. An implantable bone prosthesis comprising particles of bone, dentin, or mixtures thereof contained in a porous casing characterized in that the
5 bone or dentin particles are demineralized and the casing is flexible and porous with the pores being smaller than the particle size of the particles but large enough to permit ingress of osteogenic or mesenchymal cells.
- 10 2. The implantable bone prosthesis of Claim 1 wherein the particle size of the demineralized bone or dentin particles is in the range of about 40 to about 500 microns.
- 15 3. The implantable bone prosthesis wherein the particle size of the demineralized bone or dentin particles is in the range of about 75 to 250 microns.
- 20 4. The implantable bone prosthesis of Claim 1, 2, or 3 wherein the size of the pores in the casing is greater than about five microns and less than the smallest particle size of the demineralized bone or dentin particles.
- 25 5. The implantable bone prosthesis of Claim 1 wherein the casing is made from a fabric.
- 30 6. The implantable bone prosthesis of Claim 1 wherein the casing is made from a material that bioerodes after a predetermined time period following implantation.
7. The implantable bone prosthesis of Claim 1, 5, or 6 wherein the casing is made from crosslinked collagen.



European Patent
Office

EUROPEAN SEARCH REPORT

0082621

Application number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 82306411.8
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
A	<u>EP - A1 - 0 012 959</u> (INTERMEDICAT GMBH) --		A 61 F 1/00
A	<u>EP - A1 - 0 007 287</u> (OSTEO AG) --		
A	<u>EP - A1 - 0 006 414</u> (OSTEO AG) --		
A	<u>AT - A - 347 021</u> (LEITZ WETZLAR GMBH) --		
A	<u>DE - A1 - 2 947 875</u> (REIMER) --		
A	<u>DE - A1 - 2 755 751</u> (SUMITOMO CHEMICAL CO. LTD.) --		
A	<u>DE - A1 - 2 502 884</u> (HILDEBRANDT) --		TECHNICAL FIELDS SEARCHED (Int. Cl. 5)
A	<u>DE - A1 - 2 008 708</u> (HODOSH) -----		A 61 F 1/00
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
VIENNA	06-03-1983	EBERLE	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone			
Y : particularly relevant if combined with another document of the same category			
A : technological background			
O : non-written disclosure			
P : intermediate document			